August 2012
-
An article published in the March 17, 2011 issue of the New England Journal of Medicine details a study by researchers from the Boston University School of Medicine showing that omalizumab reduces the need for… Read more . . .
-
Almirall has launched Sativex oro-mucosal spray for the treatment of spasticity in multiple sclerosis patients in Spain. Sativex is an endocannabinoid modulator that contains THC and cannabidiol developed and manufactured by GW Pharmaceuticals. According to… Read more . . .
-
According to New York specialty pharmaceutical company Hi-Tech Pharmacal, sales of its generic fluticasone propionate nasal spray increased 562% during the quarter ending January 31, 2011. Total sales for the product reached $17.9 million for… Read more . . .
-
Submit speaker abstracts by August 1, 2011; submit nominations for the Charles G Thiel Award by November 30, 2011; and submit poster abstracts by January 13, 2012. For more information, see RDD Online. Read more . . .
-
The Pulmonary-Allergy Drugs Advisory Committee (PADAC) of the US FDA has voted to recommend approval of the 75 mcg dose of Novartis’s QAB149 indacaterol dry powder formulation for the treatment of COPD but has voted… Read more . . .
-
After a favorable end-of-Phase 2 meeting with the FDA, St. Renatus has announced that it plans to proceed to Phase 3 studies of its dental anesthetic, which is delivered as a nasal mist via a… Read more . . .
-
On March 31, 2011, 150-200 prospective buyers will gather in a Beaux Arts ballroom in New York City for ICAP Ocean Tomo’s Spring 2011 Live Auction. After having attended a welcome dinner the previous night… Read more . . .
-
AstraZeneca has announced that it will stop manufacturing the Pulmicort 100 and 200 µg/dose budesonide HFA pMDI. According to the company, the device has caused “complex manufacturing issues” and the resulting difficulty is causing it… Read more . . .
-
Briefing materials prepared by the FDA for the Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting scheduled for March 8, 2011 ask committee members to consider the safety of the higher dose of Novartis’s indacaterol inhalation powder.… Read more . . .
-
German biopharmaceutical company Revotar has announced that its Bimosiamose inhalation solution for the treatment of COPD met its primary endpoint in a Phase 2 study involving more than 75 patients with moderate-to-severe COPD. Bimosiamose is… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland